Published in Int J Gynecol Cancer on December 01, 2004
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer (2009) 1.53
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther (2011) 1.31
HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One (2007) 1.29
microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget (2014) 1.28
p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.24
The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer (2008) 1.15
Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol (2009) 1.12
Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol Ther (2011) 1.08
Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies. J Cancer Res Clin Oncol (2013) 1.08
Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer (2008) 1.05
Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS One (2012) 1.04
Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. Br J Cancer (2006) 1.01
Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Diagn Pathol (2013) 0.98
Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. Diagn Pathol (2012) 0.97
EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells? PLoS One (2012) 0.95
An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas. BMC Cancer (2011) 0.93
Propagation of human prostate cancer stem-like cells occurs through EGFR-mediated ERK activation. PLoS One (2013) 0.92
EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem (2012) 0.90
Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol (2012) 0.88
Genome-wide analysis of microRNA and mRNA expression signatures in cancer. Acta Pharmacol Sin (2015) 0.86
Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers (Basel) (2010) 0.83
Prognosis of ovarian cancer subsequent to venous thromboembolism: a nationwide Danish cohort study. BMC Cancer (2006) 0.81
Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma. Onco Targets Ther (2013) 0.81
Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer. Oncotarget (2015) 0.79
Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats. J Ovarian Res (2010) 0.79
Resveratrol, Acetyl-Resveratrol, and Polydatin Exhibit Antigrowth Activity against 3D Cell Aggregates of the SKOV-3 and OVCAR-8 Ovarian Cancer Cell Lines. Obstet Gynecol Int (2015) 0.78
HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian Tumours. Hered Cancer Clin Pract (2006) 0.75
The effect of epiregulin on epidermal growth factor receptor expression and proliferation of oral squamous cell carcinoma cell lines. Cancer Cell Int (2014) 0.75
Relevant molecular markers and targets. Gynecol Oncol (2006) 0.75
The status of epidermal growth factor receptor in borderline ovarian tumours. Oncotarget (2016) 0.75
The Putative Role of TP53 Alterations and p53 Expression in Borderline Ovarian Tumors - Correlation with Clinicopathological Features and Prognosis: A Mini-Review. J Cancer (2017) 0.75
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet (2001) 4.16
Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg (1993) 2.18
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst (2000) 1.99
Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer (1993) 1.85
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
Reproducibility of liver biopsy diagnosis in relation to the size of the specimen. Scand J Gastroenterol (1980) 1.70
Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol (1987) 1.59
A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer. Ann Oncol (2009) 1.58
Quality of life in Norwegian kidney donors. Nephrol Dial Transplant (1993) 1.47
Efficacy of Ki-67 antigen staining in Papanicolaou (Pap) smears in post-menopausal women with atypia--an audit. Cytopathology (1999) 1.41
The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol (2009) 1.40
[Screening against cervical cancer. Experiences, attitudes and knowledge of women in the county of Funen]. Ugeskr Laeger (1998) 1.37
Serum ferritin and the assessment of iron deficiency in rheumatoid arthritis. Scand J Rheumatol (1983) 1.25
Postoperative radiotherapy in Dukes' B and C carcinoma of the rectum and rectosigmoid. A randomized multicenter study. Cancer (1986) 1.22
The influence of fixation and tissue preparation on the immunohistochemical demonstration of fibronectin in human tissue. Histochemistry (1981) 1.21
The prognostic importance of miR-21 in stage II colon cancer: a population-based study. Br J Cancer (2012) 1.12
Analysis of cervical smears obtained within three years of the diagnosis of invasive cervical cancer. Acta Cytol (1991) 1.10
The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol (2010) 1.08
[Preventive examinations for cervix cancer in Denmark. Status in 1995. Plans for 1996]. Ugeskr Laeger (1996) 1.07
Fibrin and fibronectin in rheumatoid synovial membrane and rheumatoid synovial fluid. Arthritis Rheum (1983) 1.07
Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur J Cancer (2006) 1.07
Granulosa cell tumor of the ovary: a population-based study of 37 women with stage I disease. Gynecol Oncol (2001) 1.07
Consequences of persistent pain after lung cancer surgery: a nationwide questionnaire study. Acta Anaesthesiol Scand (2010) 1.06
Cells in peripheral leg lymph of normal men. Lymphology (1978) 1.04
Flow cytometric classification of biopsy specimens from cervical intraepithelial neoplasia. Cytometry (1983) 1.03
Liver biopsy in chronic aggressive hepatitis. Diagnostic reproducibility in relation to size of specimen. Scand J Gastroenterol (1983) 1.02
Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol (1999) 1.02
Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol (1997) 1.00
Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol (1980) 0.99
Bleomycin/cis-platin as neoadjuvant chemotherapy before radical radiotherapy in localized, inoperable carcinoma of the esophagus. A prospective randomized multicentre study: the second Scandinavian trial in esophageal cancer. Radiother Oncol (1992) 0.98
A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol (1987) 0.97
Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol (2001) 0.97
The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer. Pharmacogenomics J (2010) 0.97
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. Ann Oncol (2012) 0.95
Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int J Gynecol Cancer (2007) 0.95
KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer. Br J Cancer (2013) 0.94
Time to loco-regional recurrence after resection of Dukes' B and C colorectal cancer with or without adjuvant postoperative radiotherapy. A multivariate regression analysis. Br J Cancer (1992) 0.94
Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer. Gynecol Oncol (1990) 0.93
A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol (1993) 0.93
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. Br J Cancer (2013) 0.93
Use of tumour markers in monitoring the course of ovarian cancer. Ann Oncol (1999) 0.92
Postoperative radiotherapy in rectosigmoid cancer Dukes' B and C: interim report from a randomized multicentre study. Br J Cancer (1982) 0.92
A prospective study of streptokinase and heparin in the treatment of deep vein thrombosis. Acta Med Scand (1978) 0.91
The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int J Gynecol Cancer (2007) 0.91
Mucinous cystadenocarcinoma in combination with hemangiosarcoma in the ovary. Pathol Oncol Res (1999) 0.90
Gene expression in epithelial ovarian cancer: a study of intratumor heterogeneity. Int J Gynecol Cancer (2007) 0.90
Immunohistochemistry (Ki-67 and p53) as a tool in determining malignancy in smooth muscle neoplasms (exemplified by a myxoid leiomyosarcoma of the uterus). APMIS (1996) 0.89
Demonstration of fibronectin in human articular cartilage by an indirect immunoperoxidase technique. Histochemistry (1982) 0.89
Ultrasound elastography in patients with rectal cancer treated with chemoradiation. Eur J Radiol (2013) 0.89
The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy. Colorectal Dis (2008) 0.89
A cost-effectiveness analysis of cervical cancer screening: health policy implications. Health Policy (1995) 0.88
Demonstration of fibronectin in normal and injured aorta by an indirect immunoperoxidase technique. Histochemistry (1983) 0.88
Stage Ib cervical cancer during pregnancy: planned delay in treatment--case report. Eur J Gynaecol Oncol (2006) 0.88
Fibronectin in experimental granulation tissue. Acta Pathol Microbiol Immunol Scand A (1982) 0.88
A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. Br J Cancer (2004) 0.88
A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol (1993) 0.88
[Patients with early stages of endometrial cancer should be spared adjuvant radiotherapy. Danish Endometrial Cancer Group]. Ugeskr Laeger (1997) 0.87
Advanced epithelial ovarian cancer: 1993 consensus statements. Ann Oncol (1993) 0.86
DNA distribution in biopsy specimens from human cervical carcinoma investigated by flow cytometry. Virchows Arch B Cell Pathol (1979) 0.86
Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer. Gynecol Oncol (1995) 0.86
Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods. Am J Pathol (1992) 0.86
Contrast-enhanced ultrasound vs multidetector-computed tomography for detecting liver metastases in colorectal cancer: a prospective, blinded, patient-by-patient analysis. Colorectal Dis (2011) 0.86
The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol Oncol (2010) 0.85
Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group. Scand J Urol Nephrol Suppl (1991) 0.85
A randomized trial comparing two methods of cold knife conization with laser conization. Obstet Gynecol (1990) 0.85
Efficacy of the cytobrush versus the cotton swab in the collection of endocervical cells. Acta Cytol (1990) 0.85
Does plasminogen activator inhibitor-1 (PAI-1) control trophoblast invasion? A study of fetal and maternal tissue in intrauterine, tubal and molar pregnancies. Placenta (2000) 0.85
Predictive value of CA 125 during early chemotherapy of advanced ovarian cancer. Gynecol Oncol (1990) 0.85
A randomized feasibility study evaluating the effect of radiotherapy alone or combined with 5-fluorouracil in the treatment of locally recurrent or inoperable colorectal carcinoma. Acta Oncol (1993) 0.84
The use of trout erythrocytes and human lymphocytes for standardization in flow cytometry. Cytometry (1983) 0.84
Aortoiliac reconstruction in preparation for renal transplantation. Transpl Int (1993) 0.84
Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses. Gynecol Oncol (1990) 0.84
Enantiospecific synthesis of 1-azafagomine. Chemistry (2000) 0.84
Renal transplantation in insulin-treated diabetics. Transplant Proc (1979) 0.84
CA 125 in the diagnosis of pelvic masses. Eur J Cancer Clin Oncol (1989) 0.83
Importance of HLA-DR matching in cadaveric renal transplantation: a prospective one-center study of 170 transplants. N Engl J Med (1980) 0.83
A regression analysis of prognostic factors after resection of Dukes' B and C carcinoma of the rectum and rectosigmoid. Does post-operative radiotherapy change the prognosis? Br J Cancer (1988) 0.83
Blood transfusion and prognosis in Dukes' B and C colorectal cancer. Eur J Cancer (1990) 0.83
Prognostic impact of ploidy level in carcinoma of the cervix. Am J Clin Oncol (1984) 0.83
Ploidy level of human breast carcinoma. Relation to histopathologic features and hormone receptor content. Acta Radiol Oncol (1984) 0.82
EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. Ann Oncol (2009) 0.82
Cyclic hormonal treatment in ovarian cancer. A phase-II trial. Eur J Cancer Clin Oncol (1987) 0.82
Molecular factors of 5-fluorouracil metabolism in colorectal cancer: analysis of primary tumor and lymph node metastasis. Int J Oncol (2006) 0.82
The value of hyaluronidase treatment of different tissues before demonstration of fibronectin by the indirect immunoperoxidase technique. Histochemistry (1982) 0.82
Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys (1989) 0.82
Sexual dysfunction after treatment of cervical cancer. Dan Med Bull (1983) 0.81
Near-diploid karyotypes with recurrent chromosome abnormalities characterize early-stage endometrial cancer. Cancer Genet Cytogenet (1995) 0.81
Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Gynecol Oncol (1990) 0.81
Immunomagnetic removal of B-lymphoma cells from human bone marrow: a procedure for clinical use. Bone Marrow Transplant (1988) 0.81
Incorporation of fibrinogen into soluble fibrin complexes. Thromb Res (1974) 0.80
Cyclosporine in living related and cadaveric renal transplantation. Transplant Proc (1984) 0.80
Rabbit anti rat lymphocyte serum: in vitro antimacrophage activity of different types of antisera and relationship to immunosuppression. Acta Pathol Microbiol Scand B Microbiol Immunol (1973) 0.80
Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. Acta Oncol (1997) 0.80
Intergroup collaboration in ovarian cancer: a giant step forward. Ann Oncol (1999) 0.80